Intellia Therapeutics
NTLA
261 hedge funds and large institutions have $5.07B invested in Intellia Therapeutics in 2021 Q1 according to their latest regulatory filings, with 61 funds opening new positions, 110 increasing their positions, 60 reducing their positions, and 38 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 60
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
61% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 38
51% more capital invested
Capital invested by funds: $3.36B → $5.07B (+$1.71B)
33% more call options, than puts
Call options by funds: $108M | Put options by funds: $81M
8% more funds holding
Funds holding: 241 → 261 (+20)
11.2% less ownership
Funds ownership: 104.5% → 93.31% (-11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$114M |
| 2 |
Jennison Associates
New York
|
+$66.3M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$45.6M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$44.2M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$32.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$106M |
| 2 |
Morgan Stanley
New York
|
-$45M |
| 3 |
AVAI
Atlas Venture Associates IX
Boston,
Massachusetts
|
-$33.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$28.3M |
| 5 |
State Street
Boston,
Massachusetts
|
-$27.8M |
NTLA Hedge Fund Activity: Q1 2021 in Review
261 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q1 2021, worth a combined $5.07B — up 51% from $3.36B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new NTLA positions and 38 closed out — a net gain of 23 holders — while 110 added to existing stakes and 60 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $114M. The largest seller was ARK Investment Management, cutting an estimated $106M.
- 261 institutional investors held Intellia Therapeutics (NTLA) as of Q1 2021, up from 241 in Q4 2020.
- Funds reported $5.07B of Intellia Therapeutics stock for Q1 2021, up 51% quarter-over-quarter.
- 61 funds opened new Intellia Therapeutics positions in Q1 2021 and 38 closed out, a net change of +23 holders.
- The largest Intellia Therapeutics buyer in Q1 2021 was AllianceBernstein, an estimated $114M added.
- The largest Intellia Therapeutics seller in Q1 2021 was ARK Investment Management, an estimated $106M sold.
Based on aggregated 13F filings for Q1 2021.